Standard BioTools Inc. (LAB) Profit Breakdown
- 2026-06-30: Products $7.72M; Services and Other Revenue $2.82M.
- 2025-06-30: Products $8.06M; Services and Other Revenue $2.56M.
Complete filed revenue-to-profit bridge showing gross profit, operating income, pre-tax income and net income.
- Available history
- 2009-12-31 to 2026-06-30
- Data captured
Profit by product
Gross margin: each quarter (3 month)
| Quarter end | Products | Services and Other Revenue |
|---|---|---|
| 2026-06-30 | $7.72M derived | $2.82M derived |
| 2025-06-30 | $8.06M derived | $2.56M derived |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |